The Notch signaling pathway plays an important role in the bone metastasis microenvironment. Although recent evidence suggests that Notch signaling contributes to bone metastasis in breast and prostate cancer, its role and possible mechanisms in non-small cell lung cancer (NSCLC) bone metastasis are not yet clear. Here, we show that Notch3 is overexpressed in NSCLC bone metastases. The inhibition of Notch3 by small interfering RNA transfection decreased the invasion ability of NSCLC cells and transforming growth factor (TGF)-induced interleukin (IL)-6 and parathyroid hormone-related protein (pTHrP) expression in vitro. We also observed that Notch3 induced a strong morphological transformation, promoting the epithelial-mesenchymal transition (EMT). Western blotting and real-time polymerase chain reaction assays revealed that the forced overexpression of Notch3 induced the expression and activity of ZEB-1 and subsequent suppression of E-cadherin and upregulation of fibronectin, contributing to EMT and invasion. Western blotting and immunofluorescence assays showed that RNA interference-mediated ZEB-1 suppression blocked Notch-induced EMT-like transformation and subsequently reversed the observed effects on E-cadherin and downregulated fibronectin. A luciferase reporter system showed that Notch-induced ZEB-1 requires a functional binding site in the ZEB-1 promoter. In vitro invasion assays showed that the inhibition of ZEB-1 can decrease Notch3-promoted invasion and the expression of pTHrP and IL-6. Our results demonstrated that Notch upregulates ZEB-1, which contributes to TGF-β-induced EMT-like transformation and bone metastasis in NSCLC.
INTRODUCTION
Bone metastasis affects over 30-40% of metastatic lung cancer patients, causing bone fractures, severe pain, nerve compression and hypercalcemia. The resulting bone destruction releases a number of growth factors stored in the bone matrix, such as transforming growth factor-β (TGF-β), to further stimulate the malignancy of the tumor cells, completing the so-called 'vicious cycle' in bone metastasis. Although several molecular contributors to bone metastasis have been identified, effective therapies will require a more comprehensive understanding of the complex molecular and cellular network of tumor-stromal interactions in bone metastasis.
The Notch pathway regulates distinct cellular programs in the individual cell types found in the bone microenvironment. In fact, the activation of Notch signaling in murine stromal cells has been reported to promote osteoblast differentiation in a bone morphogenetic protein-dependent manner. Of pathological importance, Notch signaling in prostate cancer and breast cancer cells was shown to confer an osteogenic or osteolytic phenotype. Although classically known for its role in embryonic development, the Notch pathway is being recognized for its role in cancer deregulation. An oncogenic role for Notch was first discovered in T-cell acute lymphoblastic leukemia and subsequently extended to other malignancies, including lung, ovary, breast and skin cancers. Emerging evidence has revealed that Notch signaling is associated with bone metastasis and promotes epithelial-mesenchymal transition (EMT). 1 The bone microenvironment is rich in growth factors. During bone formation, osteoblasts incorporate a variety of growth factors, and the process of bone resorption releases and/or activates these factors into the bone microenvironment. Many of these growth factors, including TGF-β, fibroblast growth factor, insulin-like growth factor and bone morphogenetic protein-2 are able to stimulate not only the growth of metastatic cancer cells in bone but also the production and release of bone-resorbing factors from tumor cells. Among these, TGF-β stimulates parathyroid hormone-related protein (pTHrP) production in renal cell carcinoma, squamous cell carcinoma and human breast adenocarcinoma cells (MDA-MB-231). Recently, it was reported that Notch signaling is also associated with cancer progression, particularly through its regulation of EMT.
EMT is characterized by the loss of polarized organization and the downregulation of epithelial molecular markers, including E-cadherin, α-catenin and β-catenin, and simultaneously the upregulation of mesenchymal proteins, such as fibronectin, smactin and vimentin. This process is mediated by transcriptional factors such as the twist, snail and ZEB protein families. 2 The EMT program operates in several key steps of embryonic morphogenesis, enabling epithelial cells to acquire mesenchymal properties. Cancer cells exploit these programs to acquire phenotypes associated with invasiveness, the acquisition of stem-cell features, 3 resistance to chemotherapeutics, 4 resistance to anokis 5 and bone metastasis. 6 With regard to EMT inducers, the conditions of the microenvironment, such as TGF-β and hypoxia, induce the expression of certain EMT regulators including SIP, snail, 7 ZEB1 and twist. 8 It is well known that the contribution of bone-derived TGF-β plays an important role in osteolytic bone metastasis in breast and lung cancers. Bone is a rich reservoir of TGF-β, a constituent of the bone microenvironment that induces osteolytic bone metastasis. However, the functional downstream target and signaling pathway of Notch3 in TGF-β-induced non-small cell lung cancer (NSCLC) bone metastasis remain poorly defined.
In this study, we observed that Notch3 is highly expressed in non-small cell lines. Further examination showed that Notch3 was particularly upregulated in bone metastasis tissues in NSCLC. Subsequently, we employed the lentivirus-delivered small interfering RNA (siRNA) technique to knock down Notch3 in non-small cell lines. We show that Notch3 is the target of TGF-β in NSCLC bone metastasis and that the inhibition of Notch3 reverses TGF-β-induced EMT. Moreover, we found that Notch3 is involved in TGF-β-induced EMT via the transcriptional repression of ZEB-1.
MATERIALS AND METHODS

Cell culture
Bronchial epithelial cells HBE (a gift from Shanghai GeneChem, Shanghai, China) were maintained in Ham's F12 medium. Human lung adenocarcinoma cell lines H1299 and A549 were obtained from the Shanghai GeneChem Co Bank (Shanghai, China) and maintained in Dulbecco's modified Eagle medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 100 Uml − l penicillin and 0.1 mgml − 1 streptomycin under normoxia at 37°C in a modular incubator chamber (Precision Scientific, Winchester, VA, USA).
Tissue collection
Primary-site tissues from 20 cases of non-bone metastatic NSCLC and 20 cases of bone metastatic NSCLC were obtained from patients who underwent percutaneous lung puncture or biopsy of lung cancer tissue and bone metastatic tissue at the Department of Thoracic Surgery and Department of Oncology, Tangdu Hospital, Fourth Military Medical University from 2012 to 2013. All patients had a well-documented clinical history, follow-up information and no preoperative chemotherapy and/or radiation therapy. Signed informed consent was obtained from all patients contributing dissected tissues. All NSCLC cases were clinically and pathologically confirmed. The protocols were approved by the hospital's Protection of Human Subjects Committee. All tissue samples were freshly frozen at − 80°C. Total RNA from the frozen tissues was isolated with TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
RNA extraction and quantitative real-time polymerase chain reaction (RT-PCR) Total RNA was extracted from cultured cells or tissues with the TRIzol reagent (Invitrogen). cDNA was synthesized using the PrimeScript RT reagent Kit (TaKaRa, Dalian, China). Real-time PCR was performed using SYBR Premix Ex Taq II (TaKaRa) and measured using a Bio-Rad CFX96TM Manager (Bio-Rad, Hercules, CA, USA). The primers for genes were purchased from TaKaRa. The RT-PCR primers for Notch3 were (forward) 5′-CGTGGCTTCTTTCTACTGTGC and (reverse) 5′-CGTTCACCGGATTTGTGTC AC and for GAPDH were (forward) 5′-TGACTTCAACAGCGACACCCA and (reverse) 5′-CACCCTGTTGCTGTAGCCAAA. The PCR conditions were as follows: 95°C for 5 s, 55°C for 30 s and 72°C for 30 s for 45 cycles. The expression of β-actin was used as an internal control. All RT-PCR reactions were performed in triplicate. The 2 − DDCt method was used to determine the relative quantitation of gene expression levels. The results of Notch expression are expressed as Log10 . Notch cDNA vector and RNA interference lentivirus generation
The plasmid for Notch3-3 expression was constructed by Shanghai GeneChem by cloning the fragment into the BamHI and EcoRI sites of pcDNA3.0 (Invitrogen). The following sequences were used: Notch3 siRNA1, 5′-GATCCCTGCCGAAGCGACATAGATTTCAAGAGAATCTATGTCGCTT CGGCAGTTA-3′ and 5′-AGCTTAACTGCCGAAGCGACATAGATTCTCTTGAAC TATGTCGCTTCGGCAGG-3′; siRNA2, 5′-GUCAAUGUUCACUUCGCAGUU-3′ and 5′-GCGUGGAUUCGGACCA GUCUGAGAGGG-3′; SiRNA3, 5′-GATCCGC CTACCCTGCACGGAGGCTTCAAGA GAGCCTCCGTGCAGGGTAGGCTTA-3′ and 5′AGCTTAAG CC TACC CTG CACG GAG G CTCTCTTGAAGCCTCCGTGCAGG GTAGGC-3′; ZEB1-si, (forward) 5′CGGCG CAAT AACGTTAC AAAT and (reverse) 5′TTCAAGAGAATTTG TAACGTT ATTGCGCCG. After testing the overexpression and knockdown efficiencies, stem-loop oligonucleotides were synthesized and cloned into the lentivirus-based vector PsicoR (Addgene, Cambridge, MA, USA). A nontargeting stem-loop DNA PsicoR vector was generated as a negative control. Lentiviral particles were prepared as described previously.
9 A549 cells were transfected with Notch3 cDNA, siRNA lentivirus or negative control virus at 7 days in culture and examined at 10 days. The A549 cells transfected with Notch3-si1, Notch3-si2, Notch3-si3 and empty vector were designated as A549/Notch-si1, A549/ Notch-si2, A549/Notch-si3 and A549/NC, respectively. A549 and H1299 cells transfected with ZEB-1 siRNA or empty vector were designated as A549/ZEBsi or A549/NC and H1299/ZEB-si or H1299/NC, respectively. A549 or H1299 cells transfected with Notch3 vector or empty vector were designated as A549/Notch and A549/NC or H1299/notch and H1299/NC, respectively.
Western blotting
After pretreatment, whole cells or primary lung cancer tissue from patients were harvested and lysed for 30 min on ice in lysis buffer (50 mM Tris-HCl pH 7.4, 1% v/v Triton X-100, 1 mM EDTA, 1 mM leupeptin, 1 mM phenylmethylsulfonyl fluoride and 10 mM NaF). Equal amounts of protein (25 or 40 μg) were loaded onto a sodium dodecyl sulfate-polyacrylamide gel (8% polyacrylamide), subjected to electrophoresis at 200 V for 50 min, transferred to nitrocellulose and blocked overnight in blocking buffer (250 mM NaCl, 0.02% Tween 20, 5% goat serum and 3% bovine serum albumin). For western blotting, the membranes were incubated overnight with mouse or rabbit anti-Notch3 (1:1000 D11B8, Cell Signaling Technology, Danvers, MA, USA), anti-ZEB1 and anti-twist (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-E-cadherin (1:2500; BD Biosciences, San Jose, CA, USA), anti-snail (1:1000; BD Biosciences, Colorado, USA), anti-fibronectin (1:1000; BD Biosciences), anti-vimentin (1:1000; BD Biosciences) or anti-β-actin (1:4000; Sigma, St Louis, MO, USA) antibodies for 3 h. The blots were washed, and a species-matched peroxidase-conjugated secondary antibody was added (1:2000) . Labeled bands from the washed blots were detected by ECL (Amersham, Livingston, NJ, USA).
Enzyme-linked immunosorbent assay (ELISA)
A549 cells and transfected cells treated with or without TGF -β1 (10 ngml − l ) at 80% confluence were harvested, plated into 6-well tissue culture plates (1 × 10 5 cells per 2 ml per well) and incubated for 24 h at 37°C in 5% CO 2 . After a 72-h incubation at 37°C, the culture supernatants were collected, and the concentrations of pTHrP and interleukin (IL)-6 were determined using radioimmunoassays (Kitasato Otsuka Virus Assay Laboratories, Tokushima, Japan) and ELISA (R&D Systems, Minneapolis, MN, USA), respectively.
Immunofluorescence NSCLC-transfected cells or control cells were plated on sterile coverslips. After 18 h, cultures with or without TGF-β1 (10 ngml − l ) were incubated with antibodies specific for E-cadherin or fibronectin (1:200; BD Biosciences) overnight at 4°C, followed by a tetramethylrhodamine isothiocyanate-conjugated secondary antibody (Santa Cruz) for 2 h and with DAPI for 10 min (Invitrogen). All cell sections were evaluated using a 63 oil-immersion objective (numerical aperture 1.4) equipped with an image analysis program (Image Pro Plus, Imagine e Computer, Milan, Italy) and analyzed quantitatively. The integrated optical density was calculated for arbitrary areas, measuring in 10 fields for each sample using a 40x objective. Data were pooled to show a mean value, and a statistical analysis was applied to compare the results obtained from different experimental groups. The data were presented as mean7s.d.
Invasion assay
In vitro cell migration assays were performed as described previously Lakes, NJ, USA.) was overlaid onto the top chamber, and the device was placed at 37°C for 4 h. Cells (4 × 10 4 per well) with or without TGF-β1 (10 ngml − l ) stimulation were seeded onto the top chamber of the Matrigel-coated micropore membrane filter (8-μm pores); TGF-β1 was used for chemo-induction. Complete medium was added to the bottom chambers. The cells on the upper surface were removed with a wet cotton swab after 48 h, and those attached on the lower side of the membrane were fixed and stained with crystal violet before being counted under a microscope. Images of three random × 10 fields were captured for each membrane, and the number of migratory cells was counted. The mean of triplicate assays for each experimental condition was used. Similar inserts coated with Matrigel were used to determine invasive potential.
Cell migration assay
Migration assays were performed using Transwell migration chambers with 8-μm pore membranes. Cells (4 × 10 4 per well) with or without TGF-β1 (10 ngml ) and co-transfected with or without Notch3 siRNA using Lipofectamine 2000 (Invitrogen). PRL-TK was the control for the transfection efficiency in Dulbecco's modified Eagle medium without serum. pGL-ZEB-1 was amplified by PCR with primers 5′-AATTCATGGCCTGTGGATACC-3′ (forward) and 5′-CCGGGGTCCACATTCGCGTC-3′ (reverse). The promoter fragments were excised from the pUCm-T-ZEB plasmid with KpnI and HindIII and subcloned into the pGL3 vector (Promega, San Luis Obispo, CA, USA) and inserted into the pGL3 promoter vector (Promega). Luciferase activity was measured and quantitated using a luminometer with the DualLuciferase Reporter Assay System (Promega). The experiments were performed in triplicate. The results are expressed as the means of the ratio between the firefly luciferase activity and Renilla luciferase activity.
Statistical analysis
A statistical analysis was carried out using a one-way analysis of variance or an unpaired t-test, with P o0.05 for independent samples considered significant.
RESULTS
Nothc3 is overexpressed in bone metastatic NSCLC in vivo and in vitro
We first examined the expression of Notch3 in non-small lung cancer cells and bronchial epithelial cells (HBE). Western blotting and RT-PCR showed that Notch3 mRNA and protein levels were highly expressed in the non-small cell lines A549 and H1299 compared with the HBE cell line (Figures 1a and b) . To explore the role of Notch3 in NSCLC bone metastasis, an RT-PCR analysis was performed using 20 human NSCLC specimens with bone metastasis and 20 human NSCLC specimens without bone metastasis. The results showed that Notch3 mRNA was overexpressed in the NSCLC tumor tissue specimens with bone metastasis compared to the NSCLC tissue without bone metastasis. These results indicated that Notch3 expression closely correlates with bone metastasis in NSCLC.
Lenti-siRNA/Notch3 inhibits cell invasion and migration and the expression of pTHrP and IL-6 in vitro To further confirm the role of Notch3 in bone metastasis, a lentivirus-based delivery system was used to transfer Notch3 siRNA plasmids targeting Notch3 into A549 cells. As shown in Figure 2a , A549 cells infected with Notch3-si1 and Notch3-si2 exhibited effectively downregulated Notch3 expression, whereas the effect of Notch3-si3 was minimal. Therefore, A549/Notch-si1 and A549/Notch-si2 were chosen for further assays. In vitro cell invasion and migration assays showed that Notch3 downregulation in A549 cells significantly decreased their invasive and migration abilities (Figures 2c and d) . To investigate the effect of Notch3 on NSCLC with bone metastasis and the involvement of the bone microenvironment, we examined the bone metastatic specificity molecule pTHrP and IL-6 by ELISA after stimulation with TGF-β. Consistently, TGF-β induced pTHrP and IL-6 expression, whereas Notch3-si1 and Notch3-si2 significantly inhibited the TGF-β-induced expression of pTHrP and IL-6 ( Figure 2e ). In vivo assays suggested that Notch3 siRNA had the potential to inhibit the ability of bone metastatic lesions of NSCLC through the interaction with TGF-β.
Inhibition of Notch3 reverses TGF-β-induced EMT
To further explore the exact mechanism of Notch3 in bone metastasis in NSCLC, immunofluorescence staining was used to observe the expression of the epithelial marker E-cadherin and mesenchymal marker fibronectin after TGF-β stimulation. As shown in Figure 3a , the inhibition of Notch3 expression by siRNA dramatically decreased the TGF-β-induced expression of fibronectin and increased that of E-cadherin. This change represents one of the hallmarks of EMT.
To gain insight into the molecular mechanism underlying Notch in EMT, we next examined the expression of well-characterized EMT markers including twist, ZEB-1, snail, E-cadherin, fibronectin and vimentin. Western blotting and RT-PCR revealed that the inhibition of Notch3 expression by siRNA significantly decreased the TGF-β-mediated induction of ZEB-1, fibronectin and vimentin and reversed E-cadherin expression (Figures 3b and c) . Hence, both morphological and molecular changes in the cells demonstrated that Notch-si1 and Notch-si2 reversed TGF-β induced EMT, perhaps via the downregulation of EMT-related transcriptional factor ZEB-1.
Notch3 is involved in TGF-β-induced EMT by transcriptionally repressing ZEB-1 To further explore the role of ZEB-1 in Notch3-induced EMT, we constructed a ZEB-1 siRNA and Notch3 forced expression vector In an attempt to gain specific insight into the mechanisms of ZEB-1 induced by Notch3 under TGF-β stimulation, a luciferase reporter construct expressing 1016 bp of the ZEB-1 promoter (containing nucleotides − 966 to +50 harboring the Notch3 binding site) was used to address TGF-β inducibility and, specifically, the role of Notch3. As shown in Figure 4d , A549 cells transfected with pGL3-ZEB-Luc promoter showed increased luciferase activity induced by TGF-β. However, deletion of the Notch3 binding site at position − 683 resulted in a near-complete loss of TGF-β inducibility (P o 0.01 compared with the wild-type promoter). The inhibition of Notch3 expression with siRNA cotransfection decreased ZEB-1 transcriptional activity.
To further explore the mechanism of ZEB-1 regulated by Notch3, we observed the ZEB-1 transcriptional activity in Notch3 
DISCUSSION
Many studies have reported that the Notch signaling pathway plays an important role in breast and prostate cancer bone metastasis. However, the role of Notch in lung cancer bone metastasis is not yet clear. Here, we present the first evidence that Notch3 is highly expressed in NSCLC bone metastatic tissues, indicating a role for Notch3 in NSCLC bone metastasis and EMT.
It has been well documented that Notch signaling maintains the balance between cell proliferation, differentiation and apoptosis. Interestingly, it has been shown that the function of Notch signaling in tumorigenesis could be either oncogenic or antiproliferative. Indeed, Notch signaling has been shown to be antiproliferative in a limited number of tumor types, including skin cancer, human hepatocellular carcinoma and small cell lung cancer. [11] [12] [13] Regardless, the Notch pathway has been implicated in the tumorigenesis of several solid tumor malignancies, including non-small cell lung adenocarcinoma, 14 melanoma 15 and ovarian carcinoma. 16 In addition to its role in tumorigenesis, Notch signaling has also shown to directly regulate mediators of invasion, such as matrix metalloproteinase-9 and vascular endothelial growth factor. 17 Four members of the Notch receptor family have been identified, Notch1-4, and the exact role of each isoform appears to be tissue and context dependent. 18 This has been observed in an NSCLC patient with abnormally high Notch3 expression, 14 and Notch3 overexpression with the concomitant upregulation of Notch target genes of the HES family was detected in~40% of NSCLC samples. 14, 19, 20 Recently, a new paradigm for Notch signaling was found in breast cancer progression, defining a requirement for the pathway in the bone stroma, as opposed to tumor cells, during the formation of bone metastasis. 21 However, Notch signaling in NSCLC bone metastasis remains unknown. In this study, Notch3 was found to be highly expressed in NSCLC bone metastatic tissues compared to nonbone metastatic NSCLC samples. These findings were extended by evaluating a separate clinical dataset with more diverse outcome measures, such as organ-specific metastasis, which showed that elevated Notch3 levels were associated with bone metastasis.
Tumor cells produce factors that directly or indirectly stimulate osteoclastic bone resorption. These factors include pTHrP, IL-1, IL-6, prostaglandin E2, TNF and CSF-1. pTHrP is one of the major mediators of breast cancer-related osteolytic bone metastasis. 22 IL-6 is constitutively expressed by renal, bladder, prostate, cervical, glioblastoma and breast carcinoma cells, and immunohistochemical studies have demonstrated IL-6 expression in the cytoplasm of colon, prostate and breast carcinoma cells. [23] [24] [25] [26] In the present study, we observed that blocking Notch3 expression could decrease the invasive ability of NSCLC A549 cell in vitro. Further analyses suggested that Notch3 stimulates IL-6 and pTHrP, thus contributing to NSCLC bone metastasis.
Notch signaling has also been associated with cancer progression, particularly through its regulation of EMT. EMT is a conserved cellular program that confers mesenchymal features to epithelial cells during development and is postulated to provide epithelial tumor cells with migratory properties, thereby facilitating the early steps of metastasis, such as invasion. The Notch pathway regulates EMT with the contribution of several players and processes, such as TGF-β, signaling transcription factor Slug 1 and most recently hypoxia. 15, 27 Despite these associations, the functional mechanism of Notch3 in NSCLC bone metastasis has remained poorly defined to date.
Interestingly, our study found that Notch3 promotes EMT, with a near loss of epithelial markers and a concomitant increase in the expression of mesenchymal markers. However, the inhibition of Notch3 reversed these observations. Numerous experimental data support the notion that the EMT process plays an important role in tumor metastasis. 28, 29 Indeed, EMT is a cellular trans-differentiation program that enables epithelial cancer cells to acquire the characteristics of highly malignant cells. 30 Several transcription factors, including snail, 31 twist, 8 ZEB-1 and ZEB-2, 32, 33 have been found to be capable of inducing the EMT program in tumor cells. Thus, to understand the mechanism of Notch3 in NSCLC bone metastasis and the role of EMT, we examined twist, ZEB-1 and snail expression in Notch3-upregulated NSCLC cells; western blotting and an RT-PCR assay revealed that Notch3 upregulation increased ZEB-1 expression. Further data suggested that ZEB-1 contributes to Notch3-induced EMT.
It has been reported that the most prominent targets of the Notch pathway include a set of basic-helix-loop-helix factors that bind to a 5′-RTGGGAA response element:
34 nuclear factor-kappa B, vascular growth factor receptor, mammalian target of rapamycin, cyclin-D, c-myc, p21, p27 and Akt. [35] [36] [37] [38] Thus, to further explore the mechanism by which Notch3 regulates ZEB-1 and its role in EMT, we analyzed the promoter of EMT-related transcriptional factor ZEB-1. A dual luciferase reporter system confirmed that ZEB-1 is a novel target gene of Notch3 and increased its transcriptional activity, which contributed to the TGF-induced EMT phenotype.
Metastasis can be portrayed as a two-phase process. The first phase is the migration of a cancer cell to a distant organ, and the second phase is the acquisition by the cell of the ability to develop into a metastatic lesion at that distant site. A recent study reported by the Weinberg RA group suggested that the EMT program can partly explain how a cancer cell develops into a metastatic lesion at that distant site. 39 However, it has remained unclear whether metastasis is because of a metastasis-specific function. In the present study, we showed that Notch3 siRNA blocked the TGFinduced 'vicious cycle' of bone metastasis in NSCLC. We also observed that ZEB-1-mediated EMT is critically required for important Notch3 signaling processes. Overall, the results revealed a stromal-dependent mechanism for Notch signaling in support of tumor outgrowth in the bone and suggest that targeting the pathway in the tumor-associated stroma may improve treatment for NSCLC bone metastasis.
